市场调查报告书
商品编码
1245691
全球心血管数字解决方案市场规模、份额、行业趋势分析报告,按服务类型、最终用途、部署(基于云、本地)、组件(设备、软件)、地区展望和预测,2022-2028 年Global Cardiovascular Digital Solutions Market Size, Share & Industry Trends Analysis Report By Service Type, By End-use, By Deployment (Cloud-Based and On-premise), By Components (Devices and Software), By Regional Outlook and Forecast, 2022 - 2028 |
心血管数字解决方案的全球市场规模预计在预测期内以 4.8% 的复合年增长率增长,到 2028 年达到 1281 亿美元。
不适当或不正确的饮食、缺乏运动、吸烟和过量饮酒是心血管疾病(包括心脏病和中风)的最大行为风险因素。 血压升高、血糖升高、血脂升高以及超重和肥胖也可能是人们行为危险因素的症状。 在初级保健环境中,可以评估这些“中间危险因素”,并表明心脏病发作、中风和心力衰竭等并发症的风险增加。
CVD 还有其他潜在原因。 它们反映了推动社会、经济和文化变革的三大力量:城市化、人口老龄化和全球化。 遗传因素、压力和贫困也是 CVD 的预测因素。 还需要针对高血压、糖尿病和血脂过高的药物治疗,以降低患有这些疾病的人的心血管风险并阻止中风和心脏病发作。
COVID-19 影响分析
对于症状较轻的患者,在线咨询是强制性的社会疏远措施。 此外,我们还能够减轻已经因 COVID-19 病例数量而负担过重的医院的负担。 医疗物联网设备的发展也使患者能够充分利用门诊就诊并减少复诊次数。 这些设备也可以在紧急情况下使用。 此外,大流行期间遇到的资源稀缺导致了基于竞争价值的定价模型的发展。 因此,大流行对市场产生了积极影响。
市场增长因素
尖端治疗的使用增加
随着新的心血管治疗方案的开发以及 TAVR 和 3D 打印等尖端治疗技术的采用,MedTech CVD 行业正在不断发展。 医疗机构正在寻找可用于管理患者旅程的范围广泛的治疗、诊断和监测解决方案。 这些解决方案必须由正确的技术提供支持,以研究和引人注目的价值主张为后盾,并在正确的时间提供。 这将推动未来几年心血管数字解决方案市场的增长。
提供者和医疗服务的转变
越来越多的证据表明,某些 CVD 干预措施,尤其是数字工具,对患者和医生都有好处。 例如,针对患者的数字健康干预可能会减少看医生的次数,因为设备可以通过远程连接收集数据。 此外,医疗保健专业人员可以将数字解决方案用作临床决策支持工具,以输入患者数据并提出治疗建议。 因此,医疗保健提供方式的变化和医疗保健工作者的可用性已经实现了技术的使用,可以在更短的时间内为更多的患者提供服务,从而增强了市场的增长前景。
市场约束
临床试验人员不足
根据临床研究协会联合会的数据,临床试验工作者 (CTA) 和临床研究工作者 (CRA) 的需求特别高。 不幸的是,在过去的十年中,製造商和 CRO 都没有对他们的毕业生进行充分的培训,从而加剧了这个问题。 以满足该行业的研究需求。 这种人才缺口阻碍了创新技术的采用,并可能在未来几年对心血管数字解决方案市场产生不利影响。
服务类型展望
根据服务类型,心血管数字解决方案市场分为无创检测、CVD 健康信息学、心臟康復计划等。 2021 年,无创检测部门将在心血管数字解决方案市场中占据最高的收入份额。 已经引入非侵入式监测技术来收集干扰人日常生活的生理信号和特征,例如心率、心电图、血压和血糖水平。 此外,最近在谨慎和无线通信技术方面的进步使得能够从远程位置实时收集现场生理数据。
组件视角
心血管数字解决方案市场基于组件细分为设备和软件。 2021 年,软件部门在心血管数字解决方案市场中占据了重要的收入份额。 心血管健康是衡量患者从慢性心脏病康復进展的重要指标。 因此,监测心血管健康已成为治疗策略不可或缺的一部分,推动了对软件解决方案的需求。 心脏病专家和诊所工作人员可以使用技术突破和最新的软件更新轻鬆地对患者进行心臟测试。
发展前景
根据部署,心血管数字解决方案市场分为基于云的和本地的。 2021 年,基于云的细分市场在心血管数字解决方案市场中的收入份额最大。 为了摆脱预算限制,医疗保健行业需要加强资源并开发有效的方法来减少支出。 因此,医疗保健组织和医院对基于云的解决方案的采用正在增加。 基于云的解决方案已经成为必须为医疗保健组织购买和拥有所有技术的传统战略的替代方案。
最终用户展望
按最终用户划分,心血管数字解决方案市场分为医院和诊所、门诊护理中心等。 2021 年,门诊护理中心部分在心血管数字解决方案市场中占据了相当大的收入份额。 各种情况都需要使用动态心臟监测服务,例如 MCOT(移动心臟门诊遥测)。 为了持续监测心臟活动并提供所需信息,可以实时诊断出院后经导管主动脉瓣置换术 (TAVR) 患者可能发生的临床严重心律失常。
区域展望
按地区划分,分析了北美、欧洲、亚太地区和 LAMEA 的心血管数字解决方案市场。 2021 年,亚太地区心血管数字解决方案市场出现大幅增长。 这一区域市场的扩张是由亚洲国家日益老龄化的人口和心臟健康管理系统的进步推动的。 然而,亚太地区是人口密度最高、文化、社会经济水平、种族和卫生保健系统最广泛的地区,因此在心血管疾病的预防和治疗方面面临一些挑战。
市场进入者采取的主要策略是根据基数矩阵中的分析引入产品。 Apple, Inc. 和 Verily Life Sciences LLC 是心血管数字解决方案市场的先驱。 eviCore Healthcare、Koninklijke Philips N.V.和 Bardy Diagnostics, Inc. 等公司是心血管数字解决方案市场的领先创新者。
The Global Cardiovascular Digital Solutions Market size is expected to reach $128.1 billion by 2028, rising at a market growth of 4.8% CAGR during the forecast period.
Cardiovascular digital solutions are the fusion and application of digital technologies like software, sensors, wearables, smartphones, artificial intelligence, and virtual healthcare solutions. In order to develop and offer effective healthcare solutions, digital healthcare solutions are being used. The most frequent cause of morbidity and mortality, cardiovascular (CVD) illnesses, necessitates a comprehensive multi-parameter examination beyond the ECG.
For the early detection, monitoring, and treatment of cardiac problems, digital solutions are crucial. This allows for more specialized and effective cardiac care. One of the main reasons propelling the expansion of the cardiovascular digital solutions market is the rise in the prevalence of cardiovascular disorders worldwide, as well as the quickening pace of healthcare technology internationally.
Inadequate or wrong food intake, inactivity, use of tobacco, and excessive alcohol consumption are the biggest behavioral risk factors for cardiovascular diseases like heart disease and stroke. In addition, raised blood pressure, elevated blood glucose, elevated blood lipids, as well as being overweight, and obesity might be symptoms of behavioral risk factors in people. In primary care settings, these "intermediate risk factors" can be assessed and show a higher risk of complications like heart attack, stroke, and heart failure.
There are other additional underlying causes of CVDs. These reflect the three main forces that are causing social, economic, and cultural change: urbanization, population aging, and globalization. Hereditary factors, stress, and poverty are other CVD predictors. In order to lower cardiovascular risk and stop strokes and heart attacks in persons with these illnesses, the pharmacological treatment for hypertension, diabetes, and excessive blood lipids is also required.
COVID-19 Impact Analysis
Patients with mild symptoms were required to consult online as part of the social distancing procedures. Additionally, it eased the strain on hospitals already overburdened with COVID-19 patient counts. The development of Medical IoT devices also helped patients maximize outpatient care and reduce follow-up visits. These devices could also be employed in an emergency. Additionally, the resource shortage encountered during the pandemic led to the development of value-based and competitive pricing models. Therefore, the pandemic had a favorable impact on the market.
Market Growth Factors
Rising use of cutting-edge treatment methods
New cardiovascular therapy alternatives are being developed, and the MedTech CVD industry is growing, owing to the adoption of cutting-edge treatment technologies like TAVR and 3D printing. Providers are looking for a wide range of therapeutic, diagnostic, and monitoring solutions that they can use to manage the patient journey. These solutions should be empowered by the right technology, backed by research and a compelling value proposition, and made available at the appropriate time. This will propel the growth of the cardiovascular digital solutions market in the coming years.
Shifts in providers and healthcare delivery methods
There is mounting evidence that certain CVD initiatives centered on digital tools have benefited patients and physicians alike. For example, since devices may collect data via remote connectivity, digital health interventions for patients may result in fewer doctor visits. Furthermore, digital solutions can be used as clinical decision-support tools by healthcare professionals who input patient data to produce therapy suggestions. Hence, the changing methods of healthcare delivery and availability of healthcare providers have substantiated the use of technology to cater to more patients in a shorter time, which has also boosted the growth prospects for the market.
Market Restraining Factors
Insufficiently qualified staff for clinical trials
According to the Association of Clinical Research Organizations, there is a particularly great need for clinical trial associates (CTA) and clinical research associates (CRA). Unfortunately, over the past ten years, the problem has worsened because neither manufacturers nor CROs has provided graduates with enough skill training to meet the needs of the industry's research. This talent gap may hinder the adoption of innovative techniques and technology, which may have an adverse effect on the market for cardiovascular digital solutions in the years to come.
Service Type Outlook
Based on service type, the cardiovascular digital solutions market is categorized into unobtrusive testing, CVD health informatics, cardiac rehab programs, and others. The unobtrusive testing segment garnered the highest revenue share in the cardiovascular digital solutions market in 2021. Unobtrusive monitoring techniques are being deployed to collect physiological signals and characteristics that interfere with a person's daily life, like heart rate, ECG, blood pressure, and blood glucose. In addition, modern advances in inconspicuous and wireless communication technologies enable real-time on-site physiological data collection from remote sites.
Component Outlook
On the basis of components, the cardiovascular digital solutions market is divided into devices and software. The software segment recorded a significant revenue share in the cardiovascular digital solutions market in 2021. An essential marker of a patient's progress in recovering from chronic cardiac diseases is cardiovascular health. Therefore, monitoring cardiovascular health has become an integral part of the therapy strategy, which has increased the demand for software solutions. Cardiologists and clinic staff can easily do cardiac testing with patients using technological breakthroughs and the latest software updates.
Deployment Outlook
Based on deployment, the cardiovascular digital solutions market is segmented into cloud-based and on-premise. The cloud-based segment witnessed the maximum revenue share in the cardiovascular digital solutions market in 2021. To stay within budgetary restrictions, the healthcare industry needs to develop efficient ways to enhance its resources and decrease spending. Therefore, the adoption of cloud-based solutions by healthcare organizations and hospitals has increased. Cloud-based solutions have emerged as a substitute for the conventional strategy, in which institutions must buy and own all the technology.
End-Use Outlook
On the basis of end-use, the cardiovascular digital solutions market is segmented into hospitals & clinics, ambulatory care centers, and others. The ambulatory care centers segment acquired a substantial revenue share in the cardiovascular digital solutions market in 2021. Various circumstances call for using ambulatory cardiac monitoring services like MCOT (Mobile Cardiac Outpatient Telemetry). As it continually monitors heart activity and provides essential information, it enables real-time diagnosis of clinically severe arrhythmias that may arise in transcatheter aortic valve replacement (TAVR) patients after discharge.
Regional Outlook
Based on region, the cardiovascular digital solutions market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region witnessed a considerable growth rate in the cardiovascular digital solutions market in 2021. The expansion of the regional market is being driven by the rise in the elderly population and the advancement of heart health management systems in Asian nations. However, Asia Pacific presents several difficulties in the prevention and treatment of cardiovascular disease as the region with the biggest density of population and the greatest range of cultures, socioeconomic levels, ethnicities, and healthcare systems.
The major strategies followed by the market participants are Product Launches Based on the Analysis presented in the Cardinal matrix; Apple, Inc. and Verily Life Sciences LLC are the forerunners in the Cardiovascular Digital Solutions Market. Companies such as eviCore Healthcare, Koninklijke Philips N.V. and Bardy Diagnostics, Inc., are some of the key innovators in Cardiovascular Digital Solutions Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Apple, Inc., General Electric Company, Koninklijke Philips N.V., Verily Life Sciences LLC (Alphabet, Inc.), iRhythm Technologies, Inc., Bardy Diagnostics, Inc. (Hill-Rom Holdings Inc) (Baxter International Inc.), eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation), AliveCor, Inc., Cardiotrack, and HeartFlow, Inc.
Recent Strategies Deployed in Cardiovascular Digital Solutions Market
Mergers & Acquisition
Jan-2023: GE HealthCare took over IMACTIS, an innovator in the rapidly growing field of computed tomography (CT) interventional guidance across an array of care areas. Through this acquisition, GE Healthcare would be able to strengthen its recommendation offering for customers and patients.
Nov-2021: Koninklijke Philips N.V. acquired Cardiologs, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. Through his acquisition, Koninklijke Philips N.V. would be able to strengthen its diagnostics offering and cardiac monitoring with electrocardiogram (ECG) analysis, creative software technology, and reporting services.
Feb-2021: Koninklijke Philips N.V. took over BioTelemetry, Inc., a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Koninklijke Philips N.V. would be in a favorable position to enhance patient care across care environments for medical conditions and numerous diseases with the help of the combination of both organization's portfolio and service platforms.
Product Launch and Product Expansions
Nov-2022: Verily Life Sciences LLC launched Primasun. Primasun is a digital health joint venture between Verily Life Sciences LLC and ResMed Inc. Moreover, Primasun would integrate advanced healthcare research and technology into one complete digital health platform.
Sep-2022: GE Healthcare unveiled Optima IGS 320. The Optima IGS 320 is a made in India', 'AI-powered' Cath lab product. Additionally, the Cath lab advances the GE proprietary AutoRight technology where AutoRight comes with Artificial Intelligence that automatically optimizes dose and image parameters in real-time allowing clinicians to concentrate their expertise and attention on patients.
May-2022: AliveCor unveiled the KardiaComplete. The new product KardiaComplete is a complete heart health industry solution created to lower the cost of cardiac care and improved health outcomes. Additionally, this new product would be open for people diagnosed with arrhythmias and hypertension.
Nov-2021: Koninklijke Philips N.V. unveiled the new AI-enabled innovations in MR imaging. The new MR portfolio of intelligent combined solutions is created to fasten up and streamline workflows, and MR exams, optimize diagnostic quality, and aid secure the sustainability and efficiency of radiology operations.
Jan-2020: Bardy Diagnostics, Inc. unveiled the Carnation Ambulatory Monitor. The Carnation Ambulatory Monitor is the industry's only P-wave-centric arrhythmia detection device and ambulatory cardiac patch monitor. Additionally, Bardy Diagnostics, Inc. is delighted to create precise and state-of-the-art cardiac monitoring technologies that allow fresh opportunities to redefine and reimagine patient care.
Aug-2018: Koninklijke Philips N.V. unveiled the EPIQ CVx. The EPIQ CVx is the new cardiovascular ultrasound system developed on a strong EPIQ ultrasound platform. Additionally, EPIQ CVx is specially crafted to improve diagnostic confidence and streamline workflow for clinicians.
Partnerships, Collaborations & Agreements
Jan-2023: Koninklijke Philips N.V. expanded its partnership with Masimo, a global medical technology company. Under this partnership, Koninklijke Philips N.V. would boost patient monitoring abilities in-home telehealth applications with the Masimo W1™ advanced health tracking watch. Moreover, the W1 would combine with Philips's enterprise patient monitoring ecosystem to extend the forefront of telehealth and telemonitoring.
Oct-2022: GE Healthcare came into collaboration with Tribun Health, a pioneer in digital pathology workflow solutions. Under this collaboration, both organizations committed to delivering digital pathology departmental solutions that provide healthcare providers with a more comprehensive idea of patient records. Moreover, GE Healthcare would present a data management solution by combining Tribun's Health Suite data into GE Healthcare's solution.
Sep-2022: AliveCor partnered with Biotronik SE & Co KG, a leading medical device company. Under this partnership, AliveCor would integrate its FDA-cleared ECG technology with BIOTRONIK's implantable devices for cardiac rhythm diagnostics. Moreover, this would further enable a comprehensive picture of the patient's heart health while delivering essential understandings for physicians.
Mar-2022: GE Healthcare came into partnership with AliveCor, a company that is transforming cardiological care using deep learning. Under this partnership, GE Healthcare's MUSE Cardiac Management System would be integrated with the AliveCor KardiaMobile 6L ECG device. Moreover, medical-grade six-lead electrocardiograms (ECGs) taken by patients on an AliveCor KardiaMobile 6L ECG device outside of the hospital setting would be transferred to GE Healthcare's MUSE Cardiac Management System for physicians to view and evaluate.
Jan-2018: GE Healthcare came into collaboration with F. Hoffmann-La Roche AG, a Swiss multinational healthcare company that operates worldwide. Under this collaboration, GE Healthcare would co-market and co-develop digital clinical decision-support solutions to enhance therapy for critical care and oncology patients. Moreover, this collaboration would help GE Healthcare to fasten the delivery of data-driven precision health for patients, customers, and the healthcare industry.
Market Segments covered in the Report:
By Service Type
By End-use
By Deployment
By Components
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures